GlyMab®
Unlocking the therapeutic potential of tumour glycans
Scancell’s wholly-owned subsidiary, Glymab Therapeutics Ltd., is developing an exciting early-stage pipeline of high affinity GlyMab® antibodies targeting tumour specific glycans, as well as AvidiMab® Fc engineering to improve the avidity of antibodies.
High-affinity tumour specific monoclonal antibodies that target highly differentiated glycans that are preferentially expressed on tumours, validated by outlicensing of two antibodies to Genmab A/S, a global leader in antibody therapeutics.
Glymab discovery
Novel targets to the glycoproteome
The platform has a unique capability to discover and develop glycan-specific antibodies, opening up the vast number of novel and intractable targets in the glycoproteome.
High specificity antibodies to Glycan targets
Comprehensive analysis and characterisation enable higher specificity to particular glycan molecules, making the mAbs attractive development candidates. This specificity also enables their development into a range of antibody-based therapies with differing mechanisms of action.
Targets glycans preferentially expressed on tumours with little expression on normal tissue as the enzymes which attach the glycans are up or down regulated in cancer cells.
Antibody targets are expressed on multiple proteins or lipids in tumours making them attractive for multiple therapeutic modalities like ADCs, radioimmunotherapy and cell therapy.
Highly tumour specific and high target affinity. Scancell has unique know how to make high affinity IgG Mabs. Favourable safety profile due restricted expression on normal tissues.
Better specificity on clinically validated glycan targets. Higher specificity with no new glycans to target new cancers to similar expressed on normal cells resulting in potent drugs with less toxicity.
Antibody targets can be adapted to target other cancers. Groundbreaking science leads to validated preclinical results and rapid entry into the clinic.
SC134 is the lead candidate from the Glymab platform®
SC134 is being developed as a T cell engager in small cell lung cancer and is ready to move into Investigational New Drug-enabling studies and then clinical development.
FucosylGM1 is highly expressed in SCLC
134TCB has been configured to enable bivalent tumour targeting in order to maximise binding to high density tumour targets
NK Cell = natural killer cell
ADCC = antibody-dependent cellular cytotoxicity
CDC = complement dependent cytotoxicity
AvidiMab® Fc engineering facilitates prolonged antibody target occupancy and/or receptor clustering.
The technology has been shown to improve avidity of anti-glycan antibodies, immune agonist antibodies and receptor blocking antibodies.
Enhanced direct cell killing by GlyMab® through increased activity. More avid glycan binding leads to cancer cell death.
AvidiMab® promotes receptor clustering thereby improving immune signalling.
AvidiMab® promotes receptor clustering thereby improving immune signalling.
- AvidiMab® promotes receptor clustering thereby improving immune signalling.Promotes non-covalent Fc-Fc interactions of target-bound antibodies
- Facilitates receptor clustering, improved target occupancy, reduces antibody off-rate
- Increases direct killing of anti-glycan antibodies and improves efficacy of agonist antibodies
Open to licensing enquiries
commercial@scancell.co.uk
JOIN OUR MAILING LIST
Sign up for news updates to stay up to date with Scancell.